北证专精特新指数发布：50 强"小巨人"全景图，掘金高成长标的 ——北交所策略专题报告 北交所研究团队 诸海滨（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 专题：北交所发布北证专精特新指数，提供多维度投资标的和业绩基准 北交所和中证指数有限公司将于 2025 年 6 月 30 日正式发布北证专精特新指数， 为市场提供多维度投资标的和业绩基准。北交所专精特新"小巨人"上市公司证 券中选取市值最大的 50 只作为指数样本，以反映北交所专精特新上市公司证券 的整体表现。北交所定位为主要服务创新型中小企业，重点支持先进制造业和现 代服务业等领域的企业，推动传统产业转型升级，培育经济发展新动能，促进经 济高质量发展。北交所作为专精特新"主阵地"，中国特色现代资本市场"1+N+X" 政策框架的重要构成，专注服务中小企业创新发展、促进高水平科技自立自强。 截至 2025 年 6 月 6 日，北交所上市企业中，国家级专精特新"小巨人"企业达 到 146 家，数量占比 54.89%。横向比较上，北证上市企业中国家级专精特新"小 巨人"数量占比仅次于科创板的 63.71%。从业绩对比上 ...

证券代码：000718 证券简称：苏宁环球 苏宁环球股份有限公司 公司审时度势，保持战略定力，重点聚焦产品品 质，以产品品质和服务质量赢得市场认可。 3、未来公司地产项目开发规划 公司地产业务具备显著的高利润和正向现金流优 势，将按照既定战略，延续既往项目节奏，有序推进 新项目的陆续开发上市。 地产市场行情整体企稳，土地供应同比下降，公 司在优势片区话语权逐步提升，价格体系持续稳定， 今年下半年计划在公司优势区块新增地产项目，持续 提档升级，推出精品项目。 目前公司在手土地储备充足，未来在利用好现有 地块的同时，也将持续关注优质地块机会。 4、公司医美板块经营情况和竞争优势 公司持续推进地产、医美双主业发展战略，持续 投入医疗美容板块，重点打造业务版图新增长极，目 前已有 6 家医美机构，形成了六城六院的分布格局。 公司自切入医美赛道以来，厘清管理，严格把控合规、 投资者关系活动记录表 编号：2025-004 | | ☑特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | 动类别 | □现场参观 | | | □ ...

证券代码：000718 证券简称：苏宁环球 苏宁环球股份有限公司 投资者关系活动记录表 编号：2025-003 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 ☑业绩说明会 | | | □新闻发布会 □路演活动 | | 动类别 | □现场参观 | | | □其他 | | 参与单位名称 | 参加"苏宁环球—2025 年吉林辖区上市公司投资者网 | | 及人员姓名 | 上集体接待日活动"的投资者 | | 时间 | 2025 年 5 月 27 日 | | 地点 | "全景路演"网站（http://rs.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待 | 董事长张桂平先生；董事、副总裁、董事会秘书蒋立 | | 人员姓名 | 波先生；财务负责人刘得波先生 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了 | | | 回复： | | | 1、请问贵公司有全面医美转型的目标吗 | | | 回复：您好！公司将持续加大对医美业务的投入， | | | 着力提升苏亚医美品牌的市场认知度与美 ...

以下文章来源于金错刀 ，作者江源 金错刀 . 科技商业观察家。爆品战略提出者。 作者：江源 来源： 金错刀 （ID： ijincuodao ） 开年第一雷，没想到竟爆在 大型医院 头上。 最近，砸下30亿、曾被寄予厚望的重庆全域肿瘤医院突然发布公告，全面停工停产。 无独有偶。开业仅6年的西安最贵医院也发出破产倒闭公告。 就在人们为这些"巨无霸"唏嘘感叹，殊不知还有一大批同行默默在暗处倒下。倒闭的重灾区，就 是整形机构。 在TikTok难民之后，网上又多出来了一批"难民"： 诊所难民 。 因为短短的五个月内，十多家医疗美容机构在北京、上海、深圳、长沙等地疑似"跑路"，很多人 因为充卡超10万投诉无果就跑到了网上集体叫屈。 在很多人的认知里，打次水光针、做个spa疗养动辄几千；热玛吉更是过万，很多仪器还能反复 用。简直是十足的"暴利"生意，怎么还能跑路？ 但现实不容乐观。以上海、北京、广州为代表的很多一线城市，去年表面看都在狂开医美机构， 但一到年底合计新开的跟倒闭的数量差不多。 倒闭比开店多的私立整形医院，暴露出行业一个心酸真相。 01 从暴利到崩盘，打9折也卖不动 要知道，几年前的整形机构还完全不是如此。 作 ...

北交所策略专题报告 2025 年 05 月 25 日 北交所排队企业整体高质量，关注 2025 打新机会 北交所研究团队 ——北交所策略专题报告 诸海滨（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 专题：北交所排队企业整体高质量，关注 2025 北交所打新机会 上市节奏角度来看，2024 年全年北交所共上市 23 只新股。截至 2025 年 5 月 23 日，2025 年 1-5 月北交所共上市 4 家企业。从发审会节奏上来看，随着申报企业 补充 2024 年报数据的结束，下周 2 家公司上会审核，未来节奏或有提升。从首 发募集资金角度的中签率来看，募集资金较高的企业申购中签率同样较高，2024 至今北交所合计上市 27 家企业中签率均值达 0.09%，但其中首发募集资金超过 2 个亿企业的平均中签率在 0.14%，首发募集低于 2 个亿企业的平均中签率在 0.06%。从当前北交所排队企业看利润体量整体有所较高，截至 2025 年 5 月 23 日，94 家排队中企业 2024 年归母净利润均值达 8967.02 万元，高于 266 家北交 所企业 2024 年归母 ...

为给予更多优秀医疗美容技术公司、医疗机构、医疗美容医疗器械制造商及其他相关单位充分的时间准备和完 善申报材料，主办方 探美医界、思宇MedTech 现决定将 奖 项评选报名截止时间延期至 2025年5月26日 24:00 。 此次延期旨在为有意参选的各方提供更充裕的时间窗口，以便大家能够更全面、深入地展示自身在医疗美容医 疗器械领域的创新成果与卓越贡献，分享前沿经验，推动医美医疗技术的持续进步。 大会将汇聚来自全球医疗美容产业的临床专家、顶尖科学家、科技创新者、投资机构与政府监管部门，共 同探讨医美科技前沿动态、创新技术产业化路径、政策监管趋势以及市场新机遇。 举办时间： 2025年6月12日星期四 举办地点： 北京中关村展示中心 会议规模： 现场500人 参会对象： 涵盖政府、医院、医美上下游企业、投资机构等综合性高知人士 大会议程要点（拟） 为表彰医疗美容科技领域内的卓越贡献，思宇MedTech及旗下专业媒体将组织评选2025全球医美科技创 新系列奖项，并于大会开幕式现场颁发。 全球医美产业趋势与市场洞察 医美新材料、新设备、新技术 再生医学、生物刺激等技术前沿 AI赋能、数字医美与个性化治疗 监管政策与 ...

医疗美容 2025 年 05 月 21 日 投资评级：看好（首次） 行业走势图 数据来源：聚源 -19% -10% 0% 10% 19% 2024-05 2024-09 2025-01 沪深300 华熙生物通过多次产业革命重塑 HA 产业：从微生物发酵法量产到分子量精准控 制，再到探索合成生物技术精准调控 HA 实现多细胞微环境调控。华熙生物基于 糖生物学进入细胞生物学，探索衰老干预和再生医学的广阔空间。其提出"细 胞衰老本质论"，发现不同分子量 HA 可调控干细胞分化、线粒体活力及 DNA 稳定性，并开发无动物源培养基、细胞上清液等再生医学产品。产业转换能力领 先：华熙生物拥有全球最大的合成生物中试平台、超纯 HA 原料制备能力及全链 路转化生态（研发-原料-品牌），全产业链模式快速打通实验室到市场，HA 市占 率与医美三类械证数量均居行业第一。目前华熙的医美注射三类医疗器械注册证 达到 11 项，爱美客（8 项）、昊海生科（4 项）、艾尔建（9 项）、锦波生物（3 项）， 产品覆盖面部填充、唇部塑形、皮肤改善等多个场景。HA 之外，华熙生物深入 探索其他多糖，如肌肉骨骼中的硫酸软骨素，血液里的肝素等对于细 ...

Summary of InMode (INMD) Conference Call - May 19, 2025 Company Overview - InMode is an Israeli-based company specializing in medical aesthetic equipment, particularly surgical equipment that penetrates the skin [2][3] - Established around 16 years ago, with R&D and manufacturing based in Israel [2] - The company went public in February 2019 at $7 per share and has since seen significant revenue growth [8] Financial Performance - Revenue reached approximately $495 million in 2023, up from $22 million in 2017 [5][6] - Experienced a 20% revenue decline in 2024 due to economic slowdown and increased interest rates [10] - Target for 2025 is to match 2024 revenue levels [10] Product and Technology - InMode's technology includes radio frequency-assisted lipolysis and bipolar Matrix RF (Morpheus) [4][6] - The company has diversified its product line to include applications for urinary incontinence, overactive bladder, and facial rejuvenation [6] - Currently has about 12 platforms in its product portfolio, selling in 90 countries [7] Market Dynamics - The U.S. market constitutes 50% of the business, with the rest coming from international markets [19] - The company faces stronger headwinds in the U.S. compared to international markets, with consumer confidence being a significant issue [22][27] - The first quarter is typically the slowest, with Q2 expected to be stronger [30] Operational Challenges - The ongoing conflict in Israel has posed challenges, but the company has managed to maintain operations [12][35] - Tariff exposure is estimated to impact gross margins by 2% to 3% due to most products being manufactured in Israel [38][39] Marketing and Sales Strategy - The company spends heavily on marketing and sales, with a focus on both B2B and B2C strategies [16][60] - Sales and marketing expenses account for 35% to 40% of revenue, while G&A and R&D expenses are relatively low at around 3% and 4%, respectively [59][60] Future Outlook - The company is optimistic about the recovery of the aesthetic procedure market, although it does not expect an immediate surge in demand [99] - Plans to continue product innovation, with new wellness platforms expected to launch later in 2025 [52] - The management is focused on international expansion, establishing subsidiaries in Argentina and Thailand [71][72] Capital Allocation - In the past 12 months, InMode has repurchased $412 million of its stock, totaling $508 million over two years [85][87] - The company is open to various capital allocation strategies, including further buybacks, M&A, and dividends, depending on market conditions [85][86] Key Risks - Economic slowdown and rising interest rates are significant risks affecting consumer spending on aesthetic procedures [10][22] - The company is closely monitoring inflation trends in both the U.S. and Europe [23] Conclusion - InMode remains a leader in the medical aesthetics market, with a strong focus on innovation and international growth despite current economic challenges [11][72]

【环球时报驻韩国、新加坡特约记者 黎枳银 辛斌】在美国加征关税压力持续存在的背景下，日本、韩国等亚太多国GDP和贸易出现衰退或下滑趋势。日本 16日宣布其第一季度GDP按年率下降0.7%。韩国权威智库首次预测今年经济增速将降至0.8%，引发"经济衰退"担忧。亚太经合组织（APEC）15日发表报告 警告称，受美国关税政策影响，今年亚太贸易增长可能几乎停滞。不过，与多国对美贸易萎缩相反，这些国家对中国的出口增长明显，中国成为多国经济增 长的重要支撑。与此同时，亚太多国之间，特别是多国与中国正加紧升级自贸协定的谈判，以深化区域经济一体化。16日，APEC贸易部长会议通过联合声 明，与会各方强调加强区域合作，加快自贸协定谈判，以应对当前全球经济环境的不确定性。 正如APEC报告所预测，受美国关税政策影响，亚太多国经济增长面临压力。日本政府16日公布第一季度GDP数据，第一季度GDP环比下降0.2%，按年率下 降0.7%。第一季度出口下降0.6%。《日经亚洲评论》称，这是日本GDP一年来首次出现萎缩。虽然这主要是受通胀高企导致消费乏力影响，但接受日经调 查的众多经济学家担忧，美国关税影响将导致日本GDP全年萎缩0.4至 ...

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 were CNY 297.3 million, down 60.6% year over year, primarily due to a decrease in the number of medical service providers subscribing to information services [14] - Net loss attributable to So Young was CNY 33.1 million, compared to a net loss of CNY 21.2 million in the same period last year [17] - Non-GAAP net loss attributable to So Young was CNY 31.5 million, compared to non-GAAP net income of CNY 4.1 million during the same period in 2024 [17] - Basic and diluted losses per ADS were CNY 0.32, compared to CNY 0.21 in the same period of 2024 [18] - Cash and cash equivalents totaled CNY 1.1 billion as of March 31, 2025, indicating a robust cash position [18] Business Line Data and Key Metrics Changes - Revenue from aesthetic treatment services reached CNY 98.8 million, a remarkable 551.4% year over year increase, primarily due to the expansion of the aesthetic center business [15] - Total verified paid visits exceeded 45,500, up 18.5% quarter on quarter and 874.3% year over year [7] - Total number of verified paid aesthetic treatments performed surpassed 92,900, up 14% quarter on quarter and 989.4% year over year [7] - Cost of aesthetic treatment services was CNY 80.3 million, up 547.6% year over year, primarily due to the expansion of the aesthetic center business [16] Market Data and Key Metrics Changes - The aesthetic center business is gradually becoming the main growth driver, with 18 centers achieving positive monthly operating cash flow and 16 centers being profitable on a monthly basis as of March [6] - The company aims to build a differentiated nationwide light medical aesthetic chain with strong brand recognition [10] Company Strategy and Development Direction - The company is pursuing a vertical integration strategy and expanding its network of aesthetic centers in major cities [5] - A franchise model is being planned to accelerate geographic reach and network density while reducing capital expenditure pressure [32] - The company aims to develop proprietary products and control the supply chain, inspired by the Sam's Club retail model [11][19] - The focus is on high-quality proprietary products and services at fair prices, aiming to become a leading player in the medical aesthetics industry [12] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the aesthetic center business, emphasizing the importance of maintaining a sustainable financial model [32] - The company views trade tensions as an opportunity to strengthen its domestic supply chain and support import replacement [41] - The outlook for Q2 2025 expects aesthetic treatment services revenues to be between CNY 120 million and CNY 140 million, representing a 337.3% to 410.1% increase from the same period in 2024 [18][19] Other Important Information - The company has allocated additional marketing resources and implemented sales incentives to boost revenue contribution from proprietary products [9] - The number of institutions served with supply chain solutions for injectables grew to over 1,500 as of Q1 [9] Q&A Session Summary Question: How is So Young Clinic different from traditional medical institutions like Meilai and Istar? - The aesthetic center business uses a fast casual model, offering focused services with higher frequency and lower per customer spend compared to traditional models [23][24] Question: Will CapEx become a burden for the company as the clinic network grows? - The company emphasizes careful management of CapEx and plans to open around 30 new clinics per year while exploring a franchise model to reduce CapEx pressure [32][33] Question: How does the Miracle Laser create more synergy with the company's core business? - The integration of Wuhan Medical Laser improves R&D capabilities and supports the growth model by supplying high-quality, cost-effective equipment to aesthetic centers [35][36] Question: How will ongoing trade tensions impact the company's business? - The direct impact is limited, but the company sees it as an opportunity to strengthen its domestic supply chain and pivot to alternative products if necessary [41][43] Question: Can management elaborate on the company's future investment plan and cost reduction plan? - The company remains focused on sustainable growth, optimizing offerings, and increasing investment in proprietary product lines to support margin expansion [45][46]